Registration now open for Forsyth dentech 2022
Questions? Contact dentech@forsyth.org.
About Forsyth dentech 2021
Forsyth dentech 2021 established a dental innovation ecosystem for key oral health technology development stakeholders to share ideas and resources that move the market forward. By popular demand, Forsyth dentech will be an annual event, creating a new networking platform to advance innovation in the oral health bio-tech sphere.
View a recording of the first part of Forsyth dentech 2021
You can read a review of the conference here.
The Forsyth Institute, with its 111-year history of oral health innovation, presents Forsyth dentech 2021—the leading oral health technology innovation conference convening thought leaders from research, industry, academia, and venture capital. This annual event aims to accelerate innovation and launch new ventures in the oral health space. The selected presenters will have the stage to showcase their exciting new technology or pitch their business proposals for funding support. Investors and dental companies will be able to review some of the most innovative dental technologies for investment or licensing opportunities. The conference will also offer cash prizes to top technologies that will be chosen by the organizing committee.
Read a review of Forsyth dentech 2021 published in China Daily.
When:
Thursday, September 23, 2021, 12 p.m. ET – 5 p.m. ET
Cocktail reception and poster session to follow for in-person attendees: 5-7 p.m. ET
Where:
The Forsyth Institute
245 First Street
Cambridge MA, 02142
Who should attend:
• Independent inventors
• Entrepreneurs
• Start-ups
• Incubated tech teams
• Angel investors
• Venture capitalists
• Dental industry leaders
• Oral health researchers
CEO Panel Discussion
Hear from a diverse panel of experts in the dental innovation and technology development space.
Since 1989, Stanley M. Bergman has been Chairman of the Board and CEO of Henry Schein, Inc., a Fortune 500® company and the world’s largest provider of health care products and services to office-based dental and medical practitioners, with more than 19,000 Team Schein Members and operations or affiliates in 31 countries and territories. Henry Schein is a member of the S&P 500® index. In 2020, the Company’s sales reached $10.1 billion. Henry Schein has been a Fortune World’s Most Admired Company for 20 consecutive years. Mr. Bergman serves as a board member or advisor for numerous institutions including New York University College of Dentistry; the University of Pennsylvania School of Dental Medicine; the Columbia University Medical Center; University of the People; Hebrew University; Tel Aviv University; the University of the Witwatersrand Fund; The World Economic Forum’s Health Care Governors; the Business Council for International Understanding and the Metropolitan Opera.
Dr. Rena D’Souza is the Director of the National Institute of Dental and Craniofacial Research, National Institutes of Health. She is deeply committed to the organization’s mission—advance fundamental knowledge about dental, oral, and craniofacial health and disease and translate these findings into prevention, early detection, and treatment strategies that improve overall health for all individuals and communities across the lifespan. As the director of NIDCR, Dr. D’Souza oversees the institute’s annual budget of approximately $485 million, supporting basic, translational, and clinical research in areas of oral cancer, orofacial pain, tooth decay, periodontal disease, salivary gland dysfunction, and the craniofacial development and the oral complications of systemic diseases. Prior to becoming NIDCR’s director, Dr. D’Souza served in the position of Associate Vice Provost for Research for the University of Utah and as Assistant Vice President for Academic Affairs and Education for the Health Sciences. She is a past president of the American Association for Dental Research (AADR) and the International Association for Dental Research (IADR). She has authored over 150 publications and book chapters in the areas of craniofacial development, matrix biology and tissue regeneration for over 30 years.
Stephanie Hsieh is executive director of Biocom California, a non-profit trade association for the life science industry, and a board member of Meditope Biosciences, Inc., a privately held preclinical stage immuno-oncology company. Hsieh most recently served as CEO of Meditope Biosciences, growing the company from academic discovery to preclinical stage oncology, with a focused, yet diversified portfolio of immuno-therapy and oncology assets. In this capacity, Hsieh set strategic and commercial directions, securing the exclusive rights to the technology, as well as its Series A financing and pharma partnerships, and earned a reputation for operational excellence, including management of challenging P&Ls.
Dr. Jeremy Krell is a general dentist, as well as an experienced investor with a business background. He has raised rounds and generated returns for investors at ten companies, sold three, and acquired two more as a key operator. Jeremy oversaw strategic provider innovation and development at Oscar Health, a health insurance company that had an IPO in 2021. He also led provider and clinical growth initiatives at quip, a subscription oral health company, and has since built the Barchester Bay Group, a portfolio consisting of over thirty separate ventures. Jeremy is an angel investor and sits on the boards of several healthcare and dental startups. He has a fifteen-plus year proven track record with start-ups, multi-million dollar fundraises, and acquisitions.
Laurie K. McCauley is the Dean of the School of Dentistry at the University of Michigan. Dr. McCauley earned her B.S., D.D.S., M.S. and Ph.D. (Veterinary Pathobiology) all from The Ohio State University. She is a diplomate of the American Board of Periodontology, a fellow in the American Association for the Advancement of Science, a Fellow in the American College of Dentists and the International College of Dentists, a member of the National Academy of Medicine and also served on the National Institutes of Health, National Advisory Dental & Craniofacial Research Council. For more than twenty-five years, Dr. McCauley has led an active research program in cellular controls of bone remodeling, parathyroid hormone anabolic actions in bone, and prostate cancer skeletal metastasis.
Stephen Thorne founded Pacific Dental Services in 1994 and now provides business services to nearly 450 supported practices throughout California, Arizona, Nevada, Colorado, Idaho, Oregon, Washington, Texas, Utah, New Mexico, Missouri, Kansas, Georgia and Minnesota. Thorne began his work in the dental field in 1989 when his father, a dentist, offered him a job managing a struggling dental office. That first office became a big success and the foundation for creating Pacific Dental Services. Mr. Thorne was instrumental in forming the Association of Dental Support Organizations, which is the largest association of dental support organizations in America and served as the founding President for the first three years. Thorne received his BA from UCLA and his Master’s in Health Administration from Chapman University.
Dr. Ben Wu is a Co-Founder of Gradient Orthodontics. He received his prosthodontics training from Harvard School of Dental Medicine and his PhD in materials engineering from MIT. He is currently Chair of Advanced Prosthodontics, Director of Weintraub Center for Reconstructive Biotechnology, and Past Chairman of Bioengineering at UCLA. A practicing prosthodontist, Dr. Wu’s expertise is in biomaterials, material-cell interactions, and advanced biomanufacturing. Dr. Wu has Co-founded multiple startups and serves on various advisory boards to several medtech companies.
CEO Panel Moderator
Dr. Wenyuan Shi is currently the Chief Executive Officer & Chief Science Officer of the Forsyth Institute, an affiliate of the Harvard School of Dental Medicine. Prior to this position, Dr. Shi was the chairman and professor of Oral Biology at the UCLA School of Dentistry as well as Professor of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA. Dr. Shi has led multiple NIH grants to use multidisciplinary approaches to study oral microbiome with a specific focus on microbial biofilm, inter-species interaction and signal transduction. In addition, Dr. Shi’s laboratory is actively involved in the development of next generation diagnostic and therapeutic tools against oral microbial infections, including instant chairside detection of oral pathogens and peptide based targeted antimicrobial therapeutics. These translational research efforts have resulted in novel technologies that are licensed and developed by major pharmaceutical, dental and biotech companies. Dr. Shi is also the founding scientist, former chief scientific officer and chairman of the scientific advisory board of C3J Therapeutics Inc. (www.c3-jian.com).
Presenters
Cyberdontics is making robots to automate restorative dentistry, starting with dental crowns. It’s a $65B market that is 5 times bigger than the market of Invisalign or Smile Direct Club. Our go-to-market use case is dental crowns, where we enable higher-quality treatment and reduce treatment time from 2 hours over 2 visits down to one 15-minute visit.
Silk Road Therapies was established 3 years ago to develop tPTX for the treatment of Behcet’s disease as an orphan drug. Behcet’s is characterized by oral and genital aphthous ulcers and thought to have an autoimmune etiology. Peculiarly, the disease is highly concentrated along the Silk Road, an ancient trading route stretching from Istanbul to Tokyo. Timothy Cote, former Director of FDA’s Orphan Drug office and Forsyth’s entrepreneur-in residence, has brought a new therapy, tPTX, through a very successful phase 2 clinical trial, and these data will be shown. tPTX likely has broader uses in oral health for recurrent aphthous ulcers and more common, sporadic aphthous ulcers.
CellectGen is a digital health technology company, focused on developing saliva-based, consumer-facing next generation point-of-care (POC) tests, devices, and services that empower consumers to easily monitor and track the status of their health, anytime, from anywhere in less than 15 minutes. The company was founded and incorporated in the state of California in 2018. Our predictive algorithm translates whole saliva marker levels into data visual mode to help dentists and hygienists make objective data-driven decisions that cater to each individual patient. This allows the use a single saliva sample at a given time point to generate longitudinal, site specific data analytics about the levels of biomarker in a specific patient.
Developed jointly by The Forsyth Institute and dentalXr.ai, immismile is an artificial intelligence technology that assists clinicians in monitoring and predicting best outcomes for craniofacial development at an early age of the children. Developed with an exceptional and inimitable longitudinal data set from the Forsyth Twin Study, immismile can help clinicians have early diagnosis, determine the best timing and choice of potential intervention, and ultimately facilitate optimal treatment outcomes for a pediatric population.
Periodontal disease affects roughly half of all adults over 30 in the US, and if left untreated can cause bone loss and may be linked to other systemic issues such as cardiovascular disease and diabetes. The Periovance procedure will treat the disease at the general dentist’s office with a non-surgical and cost-effective visit. Periovance’s patented procedure and device for the treatment of Periodontal Disease has completed all FDA Trials and expects to receive full FDA product approval in Q1-2022. Dr. Hatice Hasturk is a Senior Member of the Staff and
Director of the Center for Clinical and Translational Research at Forsyth.
Dental caries is a major public health problem globally. None of the current preventive measures address the root cause, which is the acid production by specific commensal microorganisms. There is a critical need to establish more focused and effective preventive measures. We are developing a unique, natural and innovative orally administered probiotic for the prevention of dental caries.
Biotech Innovations is comprised of a team of orthodontists, computer scientists, engineers, and entrepreneurs who believe there is a better way to deliver predictable health care. Our mission is to deliver clinically-sound, predictable, and effective solutions for orthodontics. Through our proprietary advanced treatment planning software and patented aligner and attachment system, we are able to leverage bio-mechanical forces to achieve greater movement more efficiently. By re-engineering how tooth movement can be achieved, our aligner system can treat the simplest of cases to the most complex.
Overjet is the global leader in dental artificial intelligence. Our technology helps dentists and insurers support the best patient care with consistent diagnosis, clear visualizations, and automation of administrative tasks. We’re committed to improving oral healthcare for all. Overjet’s software analyzes radiographs and other dental media in real time and displays consistent findings on the presence and progression of caries, bone loss, calculus, and other dental pathologies. Overjet integrates with existing practice management software to deliver these AI findings through a web browser. Providers and patients can review powerful AI visualizations during treatment planning discussions.
BrickBuilt Therapeutics is a microbiome therapeutics biotechnology company focused on diseases of the oral cavity and their systemic effects. BrickBuilt was founded in 2020 to address the persistent and growing need for safe and effective drugs to treat and prevent oral diseases. Originally accepted to the IndieBio NYC Accelerator, and now part of the Harvard Life Lab, we at BrickBuilt are moving quickly with an strong R&D Platform focused on microbiology, molecular biology and translational medicine that will help attain our ambitious therapeutic goals.
Intrommune Therapeutics is a New York City-based biotechnology company dedicated to transforming and protecting the lives of people with food allergy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste, representing a new therapeutic approach for the treatment of peanut and other food allergies. Called oral mucosal immunotherapy (OMIT), it is designed to address a significant health care need in the industrialized world, where the spread of food allergies has been characterized as an “epidemic.”
Research carried out in the Sharpe group at Kings College London. As yet no company formed. IP filed for two products, ReDent and a different but related product, LithGlass GIC. Both products stimulate tertiary dentine formation by activating stem cells and/or odontoblasts to promote natural tooth repair following caries removal. Phase 1a/b clinical trial awaiting MHRA approval.
Dr. Wenyuan Shi is currently the Chief Executive Officer & Chief Science Officer of the Forsyth Institute. Dr. Shi will be representing The Forsyth Institute work in saliva-based oral microbiome diagnostics.
Denti.AI (www.denti.ai) is an intelligent automation and diagnostics company that leverages AI to analyze dental x-rays and voice dictation, identify and record pathologies, past treatments, and anatomical features. We help find diseases earlier and improve dentist productivity and revenue. The products are integrated with a range of practice management software automating the clinical workflow of smaller to largest dental groups across North America with hundreds of users. Features of the company include:
• Algorithms validated in two leading US dental schools ensure predictions are accurate
• Auto-Charting technology (patent-pending) fills patient records and treatment plans in EMR/PMS
• Analytics system allows reviewing 100% of images for QA and marketing purposes
Nocendra (a spin-out of The Forsyth Institute) is a recently established development and clinical company based in West Roxbury, Massachusetts, USA. The company has developed a drug based on new molecules and mechanisms to control inflammation without known side effects to enhance the body’s natural healing, restore health by reversing disease and regenerating tissues. Nocendra’s team has worked for more than 20 years on a new approach to resolve inflammation, with the discovery of a new class of compounds (lipoxins and resolvins) that help the body return to pre-disease conditions. Our mission is to deliver targeted solutions and develop drugs based on their discovery of natural active mediators that are both anti-inflammatory and pro-resolving, providing new approaches for the treatment of inflammatory diseases, including periodontal diseases.
We are a small group of R&D dentists that have done both clinical and university lab testing for the development of a novel line of daily preventative oral home care products. We have been assisted by UCLA dental researchers to aid our product development. Two of our dentists were biochemistry and biology researchers while in undergraduate studies and were Phi Beta Kappa and Summa Cum Laude recipients.
Gradient Orthodontics is focused on the development of direct 3D printable materials for dental applications. Its main objective is to revolutionize the billion-dollar field of orthodontic clear aligners through the synthesis of biocompatible, high performance resins for the direct 3D printing of dental aligners.
Amyndas is a private, focused, clinical-stage biopharmaceutical company and an emerging leader in the rapidly expanding field of complement therapeutics. Founded by Dr. John Lambris, a world leader in complement research at the University of Penn (https://www.lambris.com), Amyndas is developing advanced complement inhibitors to treat immune and inflammatory disorders, in areas of unmet medical need, to provide patients better and safer therapies. Using its worldwide network of complement scientists and therapeutic experts, Amyndas has developed a robust R&D program with the most diversified pipeline of C3 complement inhibitors in the field. Amyndas’ lead candidate, C3 inhibitor AMY-101, provides a novel and unique approach for the treatment of periodontal diseases.
Emanate Biomedical is developing a category-defining medical device platform to transform the standard of care for oral diseases and wounds. The company’s novel patent-protected system – personalized single-use preloaded hydrogel infused dental trays – can potentially address many of the largest unmet clinical needs in oral health. The company is headquartered in New York with a dedicated R&D center in the San Francisco Bay Area.
Moderators
Richard Anders is an investor and long-time entrepreneur. He is the Founder and Managing Director of Mass Medical Angels, a leading life science angel group. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and currently serves as managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects. He has invested in approximately two dozen early-stage startups.
Janice Bourque is Managing Director of Life Sciences for Hercules Capital, a premier specialty finance company providing debt and equity to venture capital and private equity backed, and small cap public life science companies at all stages of development with $5.9 billion committed to over 350 life science, technology and renewable energy companies. Deals include BIND Bioscience, Brickell, Cempra Pharmaceuticals, Concert Pharmaceutical, Cranford Pharmaceuticals, Dance Pharmaceuticals, deCode Genetics, Gamma Medica, Glori Energy, Medrobotics, Metuchen Pharmaceuticals, Ninepoint Medical and Pulmatrix. Previously, Ms. Bourque provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners for innovative healthcare investments for emerging and developing countries and was Senior Vice President, Group Head-Life Sciences for Comerica Bank.
Stephanie Hsieh is executive director of Biocom California, a non-profit trade association for the life science industry, and a board member of Meditope Biosciences, Inc., a privately held preclinical stage immuno-oncology company. Hsieh most recently served as CEO of Meditope Biosciences, growing the company from academic discovery to preclinical stage oncology, with a focused, yet diversified portfolio of immuno-therapy and oncology assets. In this capacity, Hsieh set strategic and commercial directions, securing the exclusive rights to the technology, as well as its Series A financing and pharma partnerships, and earned a reputation for operational excellence, including management of challenging P&Ls.
Dr. Lieberthal serves as the Chief Innovation Officer for Henry Schein, Inc., reporting to Chris Pendergast, Henry Schein’s Global Chief Technology Officer. In this role, he is at the nexus of evaluating hundreds of cutting-edge solutions and technologies, advising the many medical and dental business units of Henry Schein on important emerging trends, and helping connect the company’s global sales, marketing and distribution capabilities with important new products that help its customers run better practices and deliver excellent patient care. Previously, from 2009 until 2015, he was the Vice President, Emerging Technologies for Henry Schein, Inc., reporting to the president of Henry Schein’s Global Practice Solutions Group.
Keynote Speaker
Dai Feng, Co-Founder and Managing Director of CareCapital Advisors Limited
Dai Feng is the co-founder and managing director of CareCapital Advisors Limited, a dental focused VC and growth investor managing a $5 billion portfolio of more than 50 dental technology companies worldwide. The company invests an average of $250 million annually to support innovation and leadership. Around 80 percent of CareCapital’s portfolio is focused on dentistry, and includes everything from preventive, restorative, orthodontics, and implant to regenerative dentistry. CareCapital’s portfolio companies are worldwide, encompassing digital orthodontics from China, Germany, and the US, implant innovation out of Gottenberg, Sweden, bone regeneration innovation from Seoul Korea, and imaging technology out of Paris, France, among others. On the software front, CareCapital is invested in advanced clinical management, implant planning, orthodontics treatment planning, imaging AI, patient communication, and more. CareCapital also invests in a broad range of formats, from large multi-specialty dental hospitals with 150+ chairs serving research and public health missions, to digitally enabled small clinic networks extending care to rural communities. CareCapital’s mission is to strengthen the heritage and community of dentistry, while supporting innovative technologies and business leadership.
Please contact:
Sponsors
Platinum
Bronze
Friends of Forsyth
Forsyth dentech 2021 in the news:
Way better than a root canal, The Boston Globe, September 9, 2021
Dental Conference to Connect Innovators With Investors, Dentistry Today, July 8, 2021
Forsyth dentech 2021 convenes thought leaders in oral health technology innovation, Boston Business Journal, July 14, 2021
Forsyth Institute and Sherlock Biosciences partner to advance research and technology of human biomarkers in the oral cavity
The Forsyth Institute has entered into a strategic collaboration with Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable. The partnership is focused…
The Forsyth Institute serving as a critical resource for COVID-19 saliva diagnostic test development
As a world leader in oral biology and salivary diagnostics, the Forsyth Institute is working with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative as an advisor…
Forsyth Institute sinks its teeth into global expansion, incubator
The Forsyth Institute has its roots in groundbreaking dental research, from establishing the first pediatric dental hospital in the world, to defining the practice of removing plaque and putting fluoride…
This website will continue to be updated—please check back for additional information.
Read Forsyth’s COVID-19 Policy
